An analysis of economic incentives to encourage organ donation: evidence from Chile

Latin American Economic Review

Table 3 Option value and participation premiums to induce donation (US$ of 2013)

	Wage	Option	Participation	Savings
	Wage	Value	Premium	Costs	Costs + QALY
	(1)	(2)	(3)	(4)	(5)
(i) Prevalence rate of 14% for kidney chronic disease
Mean	625	18,321	5974	32,295	163,897
Percentiles
1	40	1169	381	49,447	181,049
5	102	2987	974	47,629	179,231
10	160	4675	1524	45,941	177,543
25	245	7169	2338	43,447	175,049
50	367	10,754	3506	39,862	171,464
75	612	17,923	5844	32,693	164,295
90	1213	35,538	11,587	15,078	146,680
95	1995	58,443	19,056	(7827)	123,775
99	4078	119,488	38,960	(68,872)	62,730
(ii) Individuals in fourth and fifth category have a non-functioning kidney
Mean	625	44,398	32,051	6218	137,820
Percentiles
1	40	2833	2045	47,783	179,385
5	102	7239	5226	43,377	174,979
10	160	11,330	8179	39,286	170,888
25	245	17,374	12,542	33,242	164,844
50	367	26,060	18,813	24,556	156,158
75	612	43,434	31,355	7182	138,784
90	1213	86,121	62,170	(35,505)	96,097
95	1995	141,626	102,239	(91,010)	40,592
99	4078	289,560	209,031	(238,944)	(107,342)

(a) In panel (i), the option value is computed per percentile weighting the VSI by 0.14 and the VSL by 0.001. In panel (ii), the option value is computed per percentile weighting the VSI by 0.10 and the VSL by 0.003. (b) Negative values (costs) in parentheses. (c) Participation premiums are computed subtracting the reservation price in Table 2 to the option value. (d) Savings in costs consider only savings to the health system. Benefits in QALY consider gains of improving the quality of life of patients after receiving an organ (see Harrison et al. (2010) and references therein)